BNP Paribas Financial Markets
NMRA icon

BNP Paribas Financial Markets’s Neumora Therapeutics NMRA Stock Holding History

BNP Paribas Financial Markets’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$145K Buy
85,228
+51,687
+154% +$98.4K ﹤0.01% 4368
2026
Q1 		$65.4K Buy
33,541
+21,156
+171% +$54.8K ﹤0.01% 4568
2025
Q4 		$22.2K Buy
12,385
+9,701
+361% +$21.2K ﹤0.01% 4991
2025
Q3 		$4.88K Sell
2,684
-493
-16% -$797 ﹤0.01% 5097
2025
Q2 		$2.33K Sell
3,177
-187,411
-98% -$142K ﹤0.01% 5039
2025
Q1 		$191K Buy
190,588
+169,703
+813% +$291K ﹤0.01% 3727
2024
Q4 		$221K Buy
+20,885
New +$250K ﹤0.01% 3804

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

BNP Paribas Financial Markets's NMRA Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Neumora Therapeutics (NMRA) stake by 154% in Q2 2026, buying an estimated $98.4K and bringing the position to 85,228 shares worth $145K. The position accounts for ﹤0.01% of the portfolio, ranked #4368.

BNP Paribas Financial Markets first reported a position in NMRA in Q4 2024 and has held it in 7 quarters since. The position peaked at $221K in Q4 2024. 99 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • BNP Paribas Financial Markets held 85,228 shares of Neumora Therapeutics worth $145K as of Q2 2026.
  • BNP Paribas Financial Markets bought 51,687 Neumora Therapeutics shares in Q2 2026, an estimated $98.4K.
  • Neumora Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4368 holding.
  • BNP Paribas Financial Markets first reported a position in Neumora Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's Neumora Therapeutics position peaked at $221K in Q4 2024.
  • 99 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.